Drug Profile
Zidovudine paediatric formulation - Mylan Laboratories
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Matrix Laboratories
- Developer Mylan Laboratories Limited
- Class Antiretrovirals; Azides; Nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 05 Feb 2019 Chemical structure information added
- 19 Oct 2011 Matrix Laboratories is now called Mylan Laboratories Inc.
- 10 Mar 2011 Registered for HIV infections (prevention of mother-to-child transmission) in USA (PO)